• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Exact Sciences, Guardant rally after Freenome colorectal cancer test results

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 03, 2024 at 11:32: AM
via Shares of Exact Sciences (EXAS) and Guardant Health (GH) are moving higher after privately held Freenome announced topline results from PREEMPT CRC, a clinical study to validate the company’s blood-based test for the early detection of colorectal cancer among average-risk adults.

article source
 

<



Similar threads

cafead
Exact Sciences-Guardant rivalry in colorectal testing market heats up
Replies
0
Views
224
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Exact Sciences kicks off multi-cancer detection study
Replies
0
Views
4
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Exact Sciences posts positive data for its capsule-on-a-string test for esophageal cancer
Replies
0
Views
74
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Exact Sciences’ next-gen colorectal cancer test hits primary goals in pivotal study
Replies
0
Views
184
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Exact Sciences posts positive data on Cologuard 2.0 ahead of readouts on rival tests
Replies
0
Views
108
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote